The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Asianet Newsable on MSN
SLS traders eye this important resistance zone ahead of key AML data readout
Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.
SELLAS Life Sciences reports successful Phase 2 trial results for SLS009 in relapsed/refractory AML, exceeding response and survival rates. SELLAS Life Sciences Group has announced that its Phase 2 ...
Kura Oncology stays a “strong buy” on KOMZIFTI FDA approval, early revenue growth, and AML trial catalysts. Click here to ...
Stocktwits on MSN
SLS stock charges ahead as AML trial buzz builds: Report claims Regal hit 80th event — retail isn’t convinced
The company’s latest official count remains 78 events, with final AML data expected after the required review process.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results